Dr Reddys Laboratories Ltd 6-K, filed Jun 26, 2024
Dr Reddys Laboratories Ltd (RDY)
About this 6-K
Dr Reddys Laboratories Ltd filed this 6-K on June 26, 2024.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
June, 2024
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit Number |
Description of Exhibits | |
| 99.1 | Intimation dated June 26, 2024 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
| Date: June 26, 2024 | By: | /s/ K Randhir Singh |
| Name: K Randhir Singh | ||
| Title: Company Secretary | ||
| 3 |
Exhibit 99.1
June 26, 2024
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Intimation of Investor call
Please find enclosed a notification titled “Dr. Reddy's to discuss acquisition of global brand Nicotinell® and related brands outside of the U.S. from Haleon plc on June 26th, 2024, call slated for June 26th, 2024 @ 7:00 PM IST / 09:30 AM ET.”
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer, and Head-CSR
Encl: as above
| CONTACT | ||
| INVESTOR RELATIONS | MEDIA RELATIONS | |
| DR. REDDY'S LABORATORIES LTD. | RICHA PERIWAL | |
| 8-2-337, Road No. 3, Banjara Hills, | richaperiwal@drreddys.com | USHA IYER |
| Hyderabad – 500034, Telangana, India. | AISHWARYA SITHARAM | ushaiyer@drreddys.com |
| aishwaryasitharam@drreddys.com | ||
Dr. Reddy's to discuss acquisition of global brand Nicotinell® and related brands outside of the U.S. from Haleon plc on June 26th, 2024
Call slated for June 26th, 2024 @ 7:00 PM IST / 09:30 AM ET
Hyderabad, India, June 26th, 2024
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will discuss the acquisition of Nicotinell® and related brands outside of the U.S. from Haleon plc on Wednesday, June 26th, 2024.
Summary of Events
| Event | Date and Time | Medium |
| Teleconference Call | June 26th, 2024, 7:00 PM IST / 09:30 AM ET | Hosted by the Company (Details below) |
| Playback of Teleconference Call | After the teleconference call till July 3rd, 2024 | Details below |
| Transcript of the Teleconference Call | Will be available on the Company’s website | Company’s website www.drreddys.com |
Teleconference Call
Following the announcement, the management of the Company will host its call to discuss the proposed acquisition. (Dial In and other details given below)
Play Back
The play back will be available after the teleconference call, till July 3rd, 2024.
For play back, dial in phone No: +91 22 7194 5757, and playback code is 37147.
Conference Joining Information
Option 1: Express Join with DiamondPass™
Pre-register with the below link and join without waiting for the operator.
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7402437&linkSecurityString=2ec0151889
| Option 2: Join through below Dial-In Numbers | |
| Universal Access Number: | +91 22 6280 1219 |
| +91 22 7115 8120 | |
| International Toll-Free Number: |
USA: 1 866 746 2133 UK: 0 808 101 1573 France: 0 800 914 745 Germany: 00 800142 43444 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to:www.drreddys.com.
Disclaimer: This release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID- 19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward- Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein.” The company assumes no obligation to update any information contained herein.